The field of quantitation of large molecules or proteins has been around for a long time. Typically, ligand binding assays (LBA) have dominated this area. However, the use of mass spectrometry in this field has gained a lot of momentum in the last several years.
This now necessitates the question “How do you choose which approach to use (LBA or MS)?” In many cases, either technology can answer the question, but there are definitely times when one technology has advantages over the other. There are several questions which might lead to specific direction, such as “what type of reagents are available?” or “do you need to differentiate a small amino acid change?”
This webinar will give an overview of each approach and discuss the types of questions that will help guide one to choose the correct technology. For the LBA, we will discuss the different types of ligand binding assays, answers to common questions that can lead to performing LBA vs. hybrid LCMS and some advantages of LBA over LCMS methodologies.
For Hybrid LCMS, we will discuss and highlight various approaches for using immunoaffinity LCMS or hybrid LCMS, from enrichment at the protein level to enrichment at the peptide level, using either bead-based or column-based enrichment strategies.
The presenters will also give examples and case studies of where each technology was applied successfully and where they had to pivot to an alternate technology. Unfortunately, many people choose which approach to use based on their capabilities or biases (a MS lab will do Hybrid LCMS and an LBA lab will do LBA). The presenters will discuss how to choose the “best” approach to answer the question. In some cases, both technologies can initially look feasible before a final decision is made. KCAS has deep expertise in both areas and can help ensure the best approach is utilized.
Franklin Spriggs, MS Director, Biopharmaceutical LBA Services, KCAS Bioanalytical and Biomarker Services
Mr. Franklin P. Spriggs received his B.S. in microbiology from Ohio University. Late 2007 saw Spriggs join Pfizer Inc. in Groton, Connecticut. While at Pfizer he began to participate in the American Association of Pharmaceutical Sciences (AAPS), where he has held positions in both the BIOTEC and Regulatory Sciences sections. In 2015 Mr. Spriggs received his M.S. in Regulatory Affairs and Quality Assurance from Temple University before transitioning out of the pharmaceutical industry to the world of the Contract Research Organization (CRO).Message Presenter
Dawn Dufield, PhD, Director, Biopharmaceutical LC-MS/MS Services, KCAS Bioanalytical and Biomarker Services
Dawn R. Dufield is the director of biopharmaceuticals (LC-MS/MS) services at KCAS. Previously she had been with Pfizer and legacy companies for over 20 years working in the quantitative LC-MS/MS field. She was one of the early pioneers of using immunoaffinity combined with LC-MS/MS to offer additional selectivity, which is now commonly referred to as Hybrid LCMS. She currently is a member of the AAPS Mass Spec Protein Bioanalysis Committee (MSPBC) and an active member of the American Society for Mass Spectrometry (ASMS). Dufield received her Ph.D. in BioAnalytical Chemistry (Honors) from the University of Kansas in Lawrence.Message Presenter
Who Should Attend?
This webinar is applicable for both pharma and biopharma individuals, including:
What You Will Learn
In this webinar, participants will learn about:
- LBA vs Hybrid LCMS
- Advantages of using LBA
- Advantages of using Hybrid LCMS
- How to choose which approach to use (LBA or MS)
- Case studies highlighting the advantage of each technology and case studies where an alternate technology was necessary
With over four decades of providing bioanalytical services to the pharma and biotech industry, KCAS knows we have the leadership, business model, strategy, depth of experience, staff development plan, capacity forecast system, proactive resource acquisition and the prioritization process that makes us a viable partner for your discovery needs.